Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

69 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lumican and versican are associated with good outcome in stage II and III colon cancer.
de Wit M, Belt EJ, Delis-van Diemen PM, Carvalho B, Coupé VM, Stockmann HB, Bril H, Beliën JA, Fijneman RJ, Meijer GA. de Wit M, et al. Among authors: bril h. Ann Surg Oncol. 2013 Dec;20 Suppl 3(Suppl 3):S348-59. doi: 10.1245/s10434-012-2441-0. Epub 2012 Jun 19. Ann Surg Oncol. 2013. PMID: 22711178 Free PMC article.
Cell cycle proteins predict recurrence in stage II and III colon cancer.
Belt EJ, Brosens RP, Delis-van Diemen PM, Bril H, Tijssen M, van Essen DF, Heymans MW, Beliën JA, Stockmann HB, Meijer S, Meijer GA. Belt EJ, et al. Among authors: bril h. Ann Surg Oncol. 2012 Jul;19 Suppl 3:S682-92. doi: 10.1245/s10434-012-2216-7. Epub 2012 Feb 4. Ann Surg Oncol. 2012. PMID: 22311118
MGL ligand expression is correlated to BRAF mutation and associated with poor survival of stage III colon cancer patients.
Lenos K, Goos JA, Vuist IM, den Uil SH, Delis-van Diemen PM, Belt EJ, Stockmann HB, Bril H, de Wit M, Carvalho B, Giblett S, Pritchard CA, Meijer GA, van Kooyk Y, Fijneman RJ, van Vliet SJ. Lenos K, et al. Among authors: bril h. Oncotarget. 2015 Sep 22;6(28):26278-90. doi: 10.18632/oncotarget.4495. Oncotarget. 2015. PMID: 26172302 Free PMC article.
Genomic profiling of stage II and III colon cancers reveals APC mutations to be associated with survival in stage III colon cancer patients.
van den Broek E, Krijgsman O, Sie D, Tijssen M, Mongera S, van de Wiel MA, Belt EJ, den Uil SH, Bril H, Stockmann HB, Ylstra B, Carvalho B, Meijer GA, Fijneman RJ. van den Broek E, et al. Among authors: bril h. Oncotarget. 2016 Nov 8;7(45):73876-73887. doi: 10.18632/oncotarget.12510. Oncotarget. 2016. PMID: 27729614 Free PMC article.
Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence.
den Uil SH, Coupé VM, Linnekamp JF, van den Broek E, Goos JA, Delis-van Diemen PM, Belt EJ, van Grieken NC, Scott PM, Vermeulen L, Medema JP, Bril H, Stockmann HB, Cormier RT, Meijer GA, Fijneman RJ. den Uil SH, et al. Among authors: bril h. Br J Cancer. 2016 Dec 6;115(12):1565-1574. doi: 10.1038/bjc.2016.376. Epub 2016 Nov 17. Br J Cancer. 2016. PMID: 27855440 Free PMC article.
Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancer.
den Uil SH, de Wit M, Slebos RJC, Delis-van Diemen PM, Sanders J, Piersma SR, Pham TV, Coupé VMH, Bril H, Stockmann HBAC, Jimenez CR, Meijer GA, Fijneman RJA. den Uil SH, et al. Among authors: bril h. Eur J Cancer. 2021 Feb;144:91-100. doi: 10.1016/j.ejca.2020.10.029. Epub 2020 Dec 17. Eur J Cancer. 2021. PMID: 33341450 Free article.
69 results